ISMPP U Optimizing Development and Communication of RWE: Strategies for Success (May 13, 2026. 11 am ET)
You did not meet the minimum attendance requirements for this event.
Loading video
This video is currently being processed. It will be ready for viewing shortly.
Thank you
This live web event has ended. Thank you for attending.
Description
Real-world evidence (RWE) is playing an increasing role in decision-making throughout healthcare. The publication development process for RWE studies can differ in important ways from the process for randomized, controlled clinical trials. This session will present current regulatory and client perspectives on RWE, and provide updates on good publication practice-related developments in the field. We shall also consider challenges and solutions related to ensuring involvement of key stakeholders from the onset of RWE development, fostering communications and collaboration between publications and HEOR/RWE teams, and addressing the reluctance of many medical journals to publish papers on RWE. The session’s overall goal will be to equip medical communications professionals with an understanding of current challenges and best practices involved in developing and effectively communicating RWE.
At the end of this session, attendees will be able to:
Explain current regulatory and client perspectives regarding RWE, and recent developments in the field (e.g., HARPER protocol template, new RWE/RWD registry)
Discuss common challenges in the publication development process for RWE studies, and review important compliance considerations.
Identify practical solutions for streamlining the RWE publication process, and for engaging with internal/external stakeholders, including KOLs and patients/care partners.
Implement strategies to improve the dissemination, interpretation, and broader understanding of RWD
Approved for 1.0 CMPP credit
Contributors
Tom Drake, MA, ISMPP CMPP, Director, Global Outcomes Group, Inc.
Tom Drake has been involved
in medical communications for over thirty years. His first job in the
health-care industry was with the international division of Rorer
Pharmaceuticals, where he spent three years working in Europe. In 1990 Tom
founded and launched the healthcare trade publication, Product Management Today
(PMT). As PMT’s editorial director, he worked with several founders of
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) along
with journal publishers and continuing medical education experts. Tom has been
involved in most areas of medical communications including global publication
planning, continuing medical education (CME), Health Economics and Outcomes
Research (HEOR), Real-World Evidence (RWE), thought-leader development and digital
and web-based communications. Tom has supported communication projects in all
major therapy areas and supported orphan drug programs.
He has been an
active member of ISMPP since 2008. He was chair of the ISMPP-U committee in
2015 and last year moved to the Advocacy and Outreach committee. Tom is also a
member of AMWA and ISPOR.
In 2015 Tom
launched the Global Outcomes Group, an independent healthcare communications
agency supporting HEOR/RWE/PRO and Medical Communications for the bio/pharma
and medical device industries.
Dr. Mike Holmes, Independent Consultant and Founder, Holmes Darcy Pharma Consulting
Dr Mike Holmes is a physician and senior
pharmaceutical executive with more than 25 years of industry leadership
(with a focus on oncology) and 10 years of clinical practice. He is
director and founder of Holmes Darcy Pharma Consulting LTD, an independent
consultancy specialising in medical affairs, clinical development,
regulatory strategy and business development. Mike is formerly Vice
President of Oncology medical affairs at Merck and Co.
Sharon F. Terry, President and CEO of Genetic Alliance,
Sharon F. Terry is President and CEO of Genetic Alliance, where she leads efforts to empower individuals, families, and communities to take charge of their health and advance biomedical research. With a Master's Degree in Theology, she entered the field as a parent advocate after her two children were diagnosed with pseudoxanthoma elasticum (PXE), cofounding PXE International in 1994. She co-discovered the ABCC6 gene, helped develop a diagnostic test, and has authored more than 150 peer-reviewed publications, including numerous clinical studies. A pioneer in patient engagement, Terry has held leadership roles across major national and international initiatives in genomics, precision medicine, and rare disease research. She also co-founded the Genetic Alliance Registry and Biobank and helped lead advocacy efforts resulting in the Genetic Information Nondiscrimination Act. Widely recognized for her impact, she has received numerous honors for advancing patient-centered research and public advocacy.
Robert Marlowe, President, Spencer-Fontayne Corporation (Moderator)
Rob Marlowe has been a medical/scientific communications
consultant on projects worldwide since 1986. Over that time, a major focus of
his has been helping develop publications to communicate data from
investigator-initiated studies and registries. As such, he has seen first-hand
the importance and challenges of RWE